Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib

Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib

Background: Melanoma patients stop responding to targeted therapies mainly due to mitogen activated protein kinase (MAPK) pathway re-activation, phosphoinositide 3 kinase/the mechanistic target of rapamycin (PI3K/mTOR) pathway activation or stromal cell influence. The future of melanoma treatment li...

Full description

Bibliographic Details
Main Authors: Diana Valentina Tudor, Ioana Bâldea, Diana Elena Olteanu, Eva Fischer-Fodor, Virag Piroska, Mihai Lupu, Tudor Călinici, Roxana Maria Decea, Gabriela Adriana Filip
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:International Journal of Molecular Sciences
Subjects:
melanoma
COX-2
celecoxib
trametinib
inflammation
Online Access:https://www.mdpi.com/1422-0067/22/9/4387

Internet

https://www.mdpi.com/1422-0067/22/9/4387

Similar Items